Kaken Pharmaceutical Co., Ltd.
Update in progress4521.T (Tokyo)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Kaken Pharmaceutical Co., Ltd. develops, manufactures, and sells medical products, devices, and agrochemicals in Japan and abroad. Its portfolio includes Clenafin, Artz, Fiblast, Ecclock, Regroth, Hernicore, and Seprafilm. It markets agrochemicals and animal health products and is active in several clinical programs, including KP-001 and Seladelpar, plus early trials like Tildacerfont. It collaborates with Alumis on ESK-001 TYK2 inhibitor and rents Bunkyo Green Court. Founded 1917, Tokyo.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTokyo (JPX)
- LocationJapan
- Founded1917
- Employees1,114
- Websitewww.kaken.co.jp